Comparison of the Use of Dexamethasone and Diclofenac Sodium in Immediate Post-Operative Care in Third Molar Surgery
Launched by HOSPITAL GERAL DE VILA PENTEADO · Feb 28, 2016
Trial Information
Current as of July 04, 2025
Unknown status
Keywords
ClinConnect Summary
STUDY DESIGN
Clinical double-blind, randomized, split-mouth trial. This study was submitted to and approved by the Human Research Ethics Committees of Hospital Geral de Vila Penteado under CAA Protocol: 34824714.8.0000.5446.
MASKING AND RANDOMIZATION
To ensure that the patient, the main researcher, the surgeon and the statistician were unaware of what drug would be used postoperatively, dexamethasone (4 mg) and diclofenac sodium (50 mg) were prepared in capsules of the same color and size, stored in similar vials and coded as drug No. 1 or drug No. 2. The drugs used in different procedur...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Patients had to have four third molars indicating the need for extraction and in any position of impact, as long as there was symmetry between the two sides.
- Exclusion Criteria:
- • Patients with a history of alcoholism, drug use, antihistamine drugs, antidepressants, cimetidine or any drug that could interfere with the painful sensitivity of the patient.
- • Patients with systemic disorders such as diabetes, hypertension, heart disease, allergy to any component of the formula, sulfa drugs and also pregnant women, nursing mothers, persons experiencing dental fear and children were excluded.
- • Patients who had pericoronitis and/or radiolucent images associated with the teeth to be extracted
About Hospital Geral De Vila Penteado
Hospital Geral de Vila Penteado is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence, the hospital provides a robust infrastructure for conducting a wide range of clinical studies, ensuring adherence to the highest ethical and regulatory standards. Our multidisciplinary team of experienced professionals collaborates closely with researchers and industry partners to facilitate groundbreaking studies that contribute to the development of new therapies and enhance treatment options for patients. By prioritizing patient safety and scientific integrity, Hospital Geral de Vila Penteado plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São Paulo, , Brazil
Patients applied
Trial Officials
Fábio Ricardo L. Sato, PhD
Principal Investigator
Hospital Geral de Vila Penteado
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials